Genetic polymorphisms predicting methotrexate blood levels and toxicity in adult non-Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 55, Issue 3, 2014, Pages 565-570

  Avivi, Irit ^a,b   Zuckerman, Tsila ^a,b   Krivoy, Norberto ^b,c,d   Efrati, Edna ^c,d  

^a Rambam Health Care Campus ^*  (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c Clinical Pharmacology Institute   (Israel)

^d Rambam Health Care Campus   (Israel)

Author keywords

Adult non Hodgkin lymphoma; Gene polymorphisms; Methotrexate toxicity; Prediction

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NEOPLASM STAGING; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES;

EID: 84894482124     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.789506     Document Type: Article

References (42)

1. Portell CA Sweetenham JW Adult lymphoblastic lymphoma Cancer J 2012 18 432-438
2. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ ECOG E2993). Blood 2008;111:1827-1833.
3. Siegal T, Goldschmidt N. CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom? Blood Rev 2012;26: 97-106.
4. Kridel R, Dietrich PY. Prevention of CNS relapse in diffuse large B-cell lymphoma. Lancet Oncol 2011;12:1258-1266
5. Saeki Y, Matsui T, Saisho K, et al. Current treatments of rheumatoid arthritis: from the "NinJa" registry. Expert Rev Clin Immunol 2012; 8: 455-465 .
6. Davis JM 3rd, Matteson EL. My treatment approach to rheumatoid arthritis. Mayo Clin Proc 2012 ; 87 : 659-673
7. Parmar S, Andersson BS, Couriel D, et al. Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study . J Clin Oncol 2011 ; 29 : 294-302
8. Ongaro A, De Mattei M, Della Porta MG, et al. Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. Haematologica 2009 ; 94 : 1391-1398 .
9. Kremer JM. Methotrexate pharmacogenomics. Ann Rheum Dis 2006 ; 65 : 1121-1123 .
10. SchmiegelowK.Advancesinindividualprediction of methotrexate toxicity: a review . Br J Haematol 2009 ; 146 : 489-503
11. Wessels JA, de Vries-Bouwstra JK, HeijmansBT, et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 2006;54:1087-1095.
12. Efrati E, Elkin H, Nahum S, et al. Population distribution of methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C risk alleles for methotrexate toxicity in Israel. Rheumatol Int 2013; 33 : 1001-1004 .
13. Lopez-LopezE, Martin-Guerrero I, Ballesteros J, et al. A systematic review and meta-analysis of MTHFR polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia. Pharmacogenomics J 2012 Oct 23. [Epub ahead of print]
14. van Ede AE, Laan RF, Blom HJ, et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 2001 ; 44 : 2525-2530 .
15. Kumagai K, Hiyama K, Oyama T, et al. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med 2003 ; 11 : 593-600
16. Bohanec Grabar P, Logar D, Lestan B, et al. Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. Eur J Clin Pharmacol 2008 ; 64 : 1057-1068 .
17. Silverton L, Dean M, Moitra K. Variation and evolution of the ABC transporter genes ABCB1, ABCC1, ABCG2, ABCG5 and ABCG8: implication for pharmacogenetics and disease. Drug Metab Drug Interact 2011;26:169-179.
18. Dean M. ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 2009;14:3-9.
19. Trevino LR, Shimasaki N, Yang W, et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 2009 ; 27 : 5972-5978 .
20. Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, et al. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2011;57:612-619.
21. Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005 ; 106 : 3760-3767 .
22. Aumente D, Buelga DS, Lukas JC, et al . Population pharma-cokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Clin Pharmacokinet 2006;45:1227-1238
23. US Department of Health and Human Services; National Institutes of Health; National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03: June 14, 2010; NIH Publication No. 09-5410. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14- QuickReference-8.5x11.pdf
24. Common Toxicity Criteria Version 2.0. Publish Date: April 30, 1999. Cancer Therapy Evaluation Program (CTEP). Available from: http://ctep.info.nih. gov
25. Reference SNP cluster report.NCBI Single Nucleotide Polymorphism database. Washington, DC: National Library of Medicine; 2012. Available from: http://www.ncbi.nlm.nih.gov/projects/SNP
26. Huang MJ, Kua KE, Teng HC, et al. Risk factors for severe hyperbilirubinemia in neonates. Pediatr Res 2004 ; 56 : 682-689 .
27. Levran O, O'Hara K, Peles E, et al. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet 2008;17:2219-2227.
28. Dervieux T, Wessels JA , Kremer JM , et al . Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis. Pharmacogenet Genomics 2012 ; 22 : 1-9 .
29. Stamp LK, Roberts RL. Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases. Pharmacogenomics 2011 ; 12 : 1449-1463 .
30. Castaldo P, Magi S, Nasti AA , et al . Clinical pharmacogenetics of methotrexate. Curr Drug Metab 2011 ; 12 : 278-286
31. Marchetti S, Pluim D, van Eijndhoven M, et al. Effect ofthe drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA. Invest New Drugs 2013 Jan 13. [Epub ahead of print]
32. Kato T, Hamada A , Mori S, et al . Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in Japanese patients with rheumatoid arthritis. Drug Metab Pharmacokinet 2012;27:192-199
33. Urano W, Taniguchi A, Yamanaka H, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002 ; 12 : 183-190 .
34. Hider SL, Woodhead M, Taylor PM, et al. Lung fibrosis in systemic sclerosis treated with a combination of ciclosporin and azathioprine. Clin Exp Rheumatol 2006 ; 24 : 215 .
35. Berkun Y, Levartovsky D, Rubinow A, et al. Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann Rheum Dis 2004;63:1227-1231.
36. Kamen BA , Vietti T. Evidence for CSF accumulation of 5-methyltetrahydrofolate during repeated courses of methotrexate plus folinic acid rescue. Br J Cancer 1989 ; 60 : 799 .
37. Borsi JD, Moe PJ. A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia. Cancer 1987 ; 60 : 5-13 .
38. EvansWE, HutsonPR, Stewart CF, et al. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion. Clin Pharmacol Ther 1983;33:301-307.
39. Jonsson P, Hoglund P, Wiebe T, et al. Methotrexate concentrations in cerebrospinal fluid and serum, and the risk of central nervous system relapse in children with acute lymphoblastic leukaemia. Anticancer Drugs 2007 ; 18 : 941-948 .
40. Neuman MG, Cohen L , Nanau RM , Hwang PA . Genetic and immune predictors for hypersensitivity syndrome to antiepileptic drugs. Transl Res 2012 ; 159 : 397-406 .
41. Chiusolo P, Giammarco S, Bellesi S, et al. The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue. Cancer Chemother Pharmacol 2012 ; 69 : 691-696 .
42. KantarM,KosovaB,CetingulN,et al.Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma 2009;50:912-917.